<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Davis, John C.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Spondyloarthritis: State of the Art</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2006</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2006-09-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">30-31</style></pages><abstract><style  face="normal" font="default" size="100%">Spondyloarthritis (SpA) are a group of diseases which includes ankylosing spondylitis (AS), reactive arthritis, arthritis/spondylitis with inflammatory bowel disease or psoriasis, and undifferentiated spondyloarthritis [Ann Intern Med 2002;136:896—907]. As a group, the SpA are one of the most common rheumatic diseases with a prevalence in the general population of 0.5—1.9% [Rheum Dis 2004;63:535—543]. This article discusses state-of-the-art treatments and therapies.</style></abstract><number><style face="normal" font="default" size="100%">3</style></number><volume><style face="normal" font="default" size="100%">6</style></volume></record></records></xml>